Country for PR: United States
Contributor: PR Newswire New York
Monday, November 15 2021 - 09:52
AsiaNet
$5M Boost to Innovation in Australia with New Illumina Genomics Lab
MELBOURNE, Australia, Nov. 15, 2021 /PRNewswire-AsiaNet/ --

- New laboratory opens in Melbourne Biomedical Precinct to accelerate the 
adoption of genomics in healthcare and agriculture in Australia.

Illumina, Inc. (NASDAQ: ILMN), the global leader in genomics, today announced 
the opening of a new, fully equipped laboratory to help Australian researchers 
and entrepreneurs make significant scientific breakthroughs in areas such as 
infectious disease, oncology, genetic disease and agriculture.

Photo - https://mma.prnewswire.com/media/1687712/Dr_Emma_Ball.jpg 

Photo - 
https://mma.prnewswire.com/media/1687713/Illumina_Innovation_Collective_Lab_Team.jpg 


Known as of the Illumina Innovation Collective, the lab will make available the 
latest in DNA sequencing, array platforms and data analysis tools, all 
supported by specialist scientific expertise to enable clinicians and 
researchers, to not only understand the genome, but also fully tap into its 
power.

Ms. Gretchen Weightman, Illumina Vice President and General Manager of Asia 
Pacific and Japan said, "Genomic discoveries offer new treatments and fresh 
hope to the patients of tomorrow as well as novel solutions for our farming 
communities. 

"During our early years, Illumina pioneered technology that could see into the 
genome. Since then, we have endeavoured to make the genome more accessible to 
ensure that the extraordinary potential of these scientific breakthroughs has a 
truly global reach.

"Our investment is a testament to the strength and breadth of the unique talent 
and culture of innovation that can be found in Australia," Ms. Weightman said.

The Illumina Innovation Collective goal is to support at least a half a dozen 
Australian research projects concurrently. It is the first genomics lab in 
Australia where Illumina's training specialists, lab scientists, clinical 
liaison officers and medical affairs teams are working shoulder to shoulder 
with genomics leaders, healthcare professionals, and patient communities, to 
fully realise the potential of genomics. 

"We are dedicated to making a positive impact on the community, not just 
through our technology, but through our actions," Ms. Weightman said. 

Illumina Innovation Collective will also host Illumina for Startups Australia, 
which is focused on creating an innovation ecosystem for the genomics industry 
by partnering with leading venture capital investors and entrepreneurs to 
create, launch, and grow genomics startups in Australia. 

Illumina for Startups initiatives also include Illumina Accelerator, founded in 
2014, and Sequoia Capital China Intelligent Healthcare Genomics Incubator, 
powered by Illumina, announced in 2021.

Dr. Emma Ball, Head of Illumina for Startups Australia said, "We are looking 
forward to partnering with the vibrant entrepreneurial and investor ecosystem 
in Australia by dedicating advanced technologies, genomics expertise, business 
guidance and networks to accelerate innovation and startups across the region. 

Through collaborative interactions, rapid delivery of solutions, and 
prioritising the needs of researchers and entrepreneurs, Illumina Innovation 
Collective will spearhead genomics innovation at a global level to make a real 
impact on human health and beyond," Dr. Ball said.

Illumina Innovation Collective is located proximate to the Victorian 
Comprehensive Cancer Centre in Melbourne, Australia. 

ABOUT ILLUMINA 

Illumina is improving human health by unlocking the power of the genome. Our 
focus on innovation has established us as the global leader in DNA sequencing 
and array-based technologies, serving customers in the research, clinical, and 
applied markets. Our products are used for applications in the life sciences, 
oncology, reproductive health, agriculture, and other emerging segments. To 
learn more, visit www.illumina.com and connect with us on Twitter ( 
https://c212.net/c/link/?t=0&l=en&o=3358427-1&h=2127114204&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Ftwitter.com%252Fillumina%26esheet%3D52359901%26newsitemid%3D20210111005930%26lan%3Den-US%26anchor%3DTwitter%26index%3D3%26md5%3Dd02070380874ca37ab3b6ca0327b04a1&a=Twitter 
), Facebook ( 
https://c212.net/c/link/?t=0&l=en&o=3358427-1&h=2360561425&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fwww.facebook.com%252Filluminainc%252F%26esheet%3D52359901%26newsitemid%3D20210111005930%26lan%3Den-US%26anchor%3DFacebook%26index%3D4%26md5%3Dcbd83a95831a32b39c5c15e4685e2ff8&a=Facebook 
), LinkedIn ( 
https://c212.net/c/link/?t=0&l=en&o=3358427-1&h=1916391202&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252F7513%26esheet%3D52359901%26newsitemid%3D20210111005930%26lan%3Den-US%26anchor%3DLinkedIn%26index%3D5%26md5%3Db955979f4cd3fe2a1339c8fcaa0a7963&a=LinkedIn 
), Instagram ( 
https://c212.net/c/link/?t=0&l=en&o=3358427-1&h=1983639473&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fwww.instagram.com%252Filluminainc%252F%26esheet%3D52359901%26newsitemid%3D20210111005930%26lan%3Den-US%26anchor%3DInstagram%26index%3D6%26md5%3D42318aefd9c28ea0c5b3db251aae67e6&a=Instagram 
), and YouTube ( 
https://c212.net/c/link/?t=0&l=en&o=3358427-1&h=1190555914&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fwww.youtube.com%252Fuser%252FIlluminaInc%26esheet%3D52359901%26newsitemid%3D20210111005930%26lan%3Den-US%26anchor%3DYouTube%26index%3D7%26md5%3D1f238e7dc2e8c3ff19983b828f63f82b&a=YouTube 
).

Investors:
Brian Blanchett
+1.858.291.6421
ir@illumina.com 

ANZ, Asia Pacific, Japan, Public Relations: 
Lisa Maguire Phone:
0499 328 0454 
lmaguire@illumina.com   

Weber Shandwick - Tanya West 
Phone: 0406 907 845 
tanya.west@webershandwick.com.au 

SOURCE  Illumina, Inc.